Special Issue

Advanced Research on Endometriosis and Adenomyosis

Message from the Guest Editors

This Special Issue of *Biomedicines* will mainly focus on the research progress of the pathogenesis, diagnosis and treatment of endometriosis. The pathophysiologies of endometriosis and adenomyosis are extremely similar, and both are common chronic gynecological disorders. However, the pathogenic mechanisms are still unclear, which limits the options of diagnosis and treatment. Therefore, we devote ourselves to agglomerate brilliant ideas and information together from all over the world to form better diagnosis and treatment for the patients with endometriosis or adenomyosis. We cordially invite authors in the field to submit the research or review articles related to this field of medicine.

Guest Editors

Dr. Xinmei Zhang

Women's Hospital, Zhejiang University School of Medicine, No. 1 Xue Shi Road, Hangzhou 310006, China

Prof. Dr. Chi Chiu Wang

Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong

Deadline for manuscript submissions

closed (31 May 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/189718

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).